<br>        Inclusion Criteria:<br><br>          -  At least 18 years of age.<br><br>          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.<br><br>          -  Measurable disease as defined by RECIST criteria<br><br>          -  Adequate organ and bone marrow function as evidenced by:<br><br>               -  Hemoglobin >= 9 g/dL;<br><br>               -  ANC >= 1.5 x 109/L;<br><br>               -  Platelet count >= 100 x 109/L;<br><br>               -  Serum creatinine < 1.5 mg/dL or creatinine clearance > 60 mL/min;<br><br>               -  AST, ALT, and alkaline phosphatase <= 2.5 x upper limit of normal (ULN) if<br>                  without liver metastasis and <= 5.0 x ULN if liver metastasis;<br><br>               -  Total bilirubin <= 2.0 x ULN.<br><br>          -  Men and women of childbearing potential must be willing to consent to using effective<br>             double barrier contraception (eg, hormonal contraceptives, bilateral tubal ligation,<br>             barrier with spermicidal, intrauterine device) while on treatment and for 3 months<br>             thereafter.<br><br>          -  All female subjects of childbearing potential must have a negative pregnancy test<br>             (serum or urine) result <= 72 hours before initiating study treatment.<br><br>          -  Subjects must be fully informed about their illness and the investigational nature of<br>             the study protocol (including foreseeable risks and possible side effects) and must<br>             sign and date an IEC approved ICF before performance of any study specific procedures<br>             or tests.<br><br>        Exclusion Criteria:<br><br>          -  Anticipation of need for a major surgical procedure or radiotherapy (RT) during the<br>             study.<br><br>          -  Prior treatment with chemotherapy for their disease.<br><br>          -  History of any of the following conditions within 6 months before study enrolment:<br>             myocardial infarction; New York Heart Association (NYHA) class II or higher<br>             severe/unstable angina pectoris; coronary/peripheral artery bypass graft; NYHA class<br>             III or IV congestive heart failure; cerebrovascular accident or transient ischemic<br>             attack, pulmonary embolism, or other clinically significant thromboembolic event;<br>             clinically significant pulmonary disease (eg, severe chronic obstructive pulmonary<br>             disease or asthma); clinically significant pulmonary edema or anasarca..  See Section<br>             17.2 for NYHA Classification.<br><br>          -  Clinically significant pleural or pericardial effusions.<br><br>          -  Grade 2 or higher current peripheral neuropathy (See Section 17.3; NCI CTCAE, Version<br>             3.0).<br><br>          -  Clinically active brain metastasis (ie, untreated, still requiring therapy with<br>             steroids or RT, or with progression within 4 weeks after completion of RT); an<br>             uncontrolled seizure disorder; spinal cord compression; or carcinomatous meningitis.<br><br>          -  History of malignancy other than NSCLC, unless there is the expectation that the<br>             malignancy has been cured, and tumor specific treatment for the malignancy has not<br>             been administered within the previous 5 years.<br><br>          -  Clinically significant active infection that requires antibiotic therapy or Human<br>             Immunodeficiency Virus (HIV)  positive subjects receiving antiretroviral therapy.<br><br>          -  Previous treatment with chemotherapy, CS 1008, other agonistic DR 5 or DR 4<br>             antibodies, or with TRAIL.<br><br>          -  Pregnant or breast feeding.<br><br>          -  Known history of hypersensitivity reactions to any of the components of CS 1008,<br>             carboplatin, or paclitaxel formulations.<br><br>          -  Serious intercurrent medical or psychiatric illnesses or any other conditions that in<br>             the opinion of the Investigator would impair the ability to give informed consent or<br>             unacceptably reduce protocol compliance or safety of the study treatment.<br>